Author: admin

  • Top Wall Street analysts prefer these 3 dividend-paying stocks for consistent income

    Top Wall Street analysts prefer these 3 dividend-paying stocks for consistent income

    Two drilling rigs are pictured in Midland, Texas, U.S., Oct. 8, 2024.

    Georgina Mccartney | Reuters

    Many pundits are expecting major indices to be volatile due to macro uncertainty. Moreover, on average, September has historically been the worst month for U.S. stocks.

    Investors seeking consistent income despite a volatile market can consider adding dividend-paying stocks to their portfolios. To this end, they can rely on the recommendations of top Wall Street analysts, who with their expertise can help select attractive dividend stocks with strong fundamentals.

    Here are three dividend-paying stocks, highlighted by Wall Street’s top pros, as tracked by TipRanks, a platform that ranks analysts based on their past performance.

    Archrock

    This week’s first dividend pick is Archrock (AROC), an energy infrastructure company with a primary focus on midstream natural gas compression. The company paid a dividend of 21 cents per share for the second quarter, an increase of about 11% over the first-quarter dividend. At an annualized dividend of 84 cents, AROC offers a yield of 3.3%.

    In a recent research note, Mizuho analyst Gabriel Moreen updated the models and price targets for master limited partnerships (MLPs) and midstream companies. Moreen reiterated a buy rating on Archrock stock and modestly raised the price forecast to $32 from $31. Interestingly, TipRanks’ AI Analyst has an “outperform” rating on AROC stock with a price target of $27.

    Moreen said AROC continues to “distinguish itself with exceptional balance sheet flexibility,” which allows it to deliver not only solid capital returns like its $28.8 million share repurchase in the second quarter, but also supports higher capital spending and dividend expansion.

    Notably, the 5-star analyst highlighted that AROC indicated that it expects its dividend to increase consistently with recent dividends per share growth, if the business performs. Consequently, Moreen increased his dividend per share estimates for fiscal 2025, 2026, and 2027 to 83 cents, 93 cents and $1.02, reflecting a year-over-year growth of 20%, 12% and 10%, respectively.

    The analyst stated that AROC demonstrated strong operational momentum by raising its adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) guidance for the second consecutive quarter, although there were some one-time items. Moreover, Moreen believes that Archrock’s aggressive capex outlook stands out, as it clearly indicates that the company is seeing solid demand for new orders despite the volatility following “liberation day.”

    Moreen ranks No. 112 among more than 10,000 analysts tracked by TipRanks. His ratings have been profitable 76% of the time, delivering an average return of 13.9%. See Archrock Ownership Structure on TipRanks.

    Brookfield Infrastructure Partners

    Next up is Brookfield Infrastructure Partners (BIP), a leading global infrastructure company that owns and operates diversified, long-life assets in the utilities, transport, midstream and data sectors. BIP declared a quarterly distribution of 43 cents per unit payable on Sept. 29, reflecting a 6% year-over-year increase. BIP stock offers a dividend yield of 5.6%.

    Recently, Jefferies analyst Sam Burwell resumed coverage of Brookfield Infrastructure stock with a buy rating and a price target of $35. In comparison, TipRanks’ AI Analyst has a price target of $34 but a “neutral” rating.

    Burwell stated that BIP remains a “unique beast” with an expanding footprint. He noted three significant acquisitions since April – the Colonial Pipeline, rail car leasing with GATX, and the Hotwire fiber-to-home business, all of which were U.S.-focused and highly contracted. Additionally, all three have strengthened BIP’s midstream, transport, and data businesses, respectively.

    “While BIP’s broad footprint remains complex, we tend to view positively that the YTD acquisitions have been in the US and that most of the divestitures have been ex-North America,” said Burwell.

    The top-rated analyst contended that while BIP stock has stagnated over the last few years, its upcoming investor day provides an opportunity to help the market better understand the transactions made in 2025. Burwell expects BIP’s funds from operations (FFO) to grow at a nearly 9% compound annual growth rate (CAGR), excluding to-be-announced capital recycling. Burwell also expects solid distribution growth at about 6.5% CAGR through 2027.

    Burwell ranks No. 848 among more than 10,000 analysts tracked by TipRanks. His ratings have been successful 64% of the time, delivering an average return of 15.7%. See Brookfield Infrastructure Statistics on TipRanks.

    Permian Resources

    Another dividend-paying energy stock is Permian Resources (PR). It is an independent oil and natural gas company having assets in the Permian Basin, with a concentration in the core of the Delaware Basin. The company declared a base dividend of 15 cents per share for the third quarter of 2025, payable on Sept. 30. At an annualized dividend per share of 60 cents, PR stock offers a dividend yield of 4.3%.

    Recently, Goldman Sachs analyst Neil Mehta reaffirmed a buy rating on Permian stock with a price forecast of $17. Likewise, TipRanks’ AI Analyst has an “outperform” rating on PR stock with a price target of $16.50.

    Mehta highlighted that Permian Resources continued to ramp its operations in the second quarter across the acquired assets from APA Corp. and other smaller bolt-on acquisitions. Moreover, the company announced new transportation and marketing agreements to enhance oil and natural gas netbacks, which are estimated to drive incremental free cash flow of over $50 million in 2026 compared with 2024.

    Despite the uncertainty around oil prices, the 5-star analyst remains bullish on Permian Resources, given its cost optimization efforts and focus on delivering higher free cash flow per share. The analyst noted management’s commentary about PR’s solid balance sheet, which allows it to make strategic investments without disrupting its capital allocation priorities, such as increasing cash on the balance sheet, share repurchases, and debt reduction.

    “We believe PR’s focus on opportunistically acquiring high-quality assets along with consistent grassroots acquisitions can drive long-term shareholder value,” said Mehta.

    Mehta ranks No. 670 among more than 10,000 analysts tracked by TipRanks. His ratings have been successful 59% of the time, delivering an average return of 9%. See Permian Resources Insider Trading Activity on TipRanks.

    Continue Reading

  • Pain Medicine Needs an Open-Access Data Revolution

    Pain Medicine Needs an Open-Access Data Revolution

    In oncology, open-access data has reshaped both research and patient care. Large, centralized repositories—such as The Cancer Genome Atlas—have created a “rising tide lifts all boats” effect. By sharing data, competing institutions and companies gain deeper insights, and the field benefits from faster innovation in diagnostics, therapeutics, and personalized care.1 Centralized datasets also enable artificial intelligence (AI) to perform at its best—identifying complex patterns, uncovering mechanism-based insights, and detecting subtle signals that smaller datasets miss.2 For example, AI trained on these repositories has predicted tumor drug responses and identified novel genetic subtypes, helping clinicians tailor treatments to individual patients.3 The lesson is clear: when data are pooled and made accessible, progress toward precision medicine accelerates for everyone.

    Per a 2023 study, chronic pain affects over 51.6 million Americans4 and carries an economic burden exceeding $722.8 billion (in 2021 USD) annually,5 yet pain medicine lacks a data infrastructure comparable to oncology. National Institutes of Health (NIH) has made notable strides: federally funded studies must share raw individual-level clinical trial data, and the NIH Toolbox6 has demonstrated how validated, standardized measures can be implemented across institutions to improve comparability. Within pain research, the NIH Helping to End Addiction Long Term (HEAL) Initiative’s Common Data Elements (CDE) Program7 provides standardized measures to harmonize studies and facilitate cross-study comparisons. Supporting multisite trials, the EPPIC-Net Data Coordinating Center (DCC)8 manages data collection, ensures quality, and enables harmonization across sites. Together, these efforts establish an important foundation for a more coordinated and accessible pain data ecosystem.

    However, pain medicine operates with a stark disadvantage: what oncology has that pain medicine currently lacks is an abundance of public funding. Cancer research benefits from a dedicated National Cancer Institute, with stable and expansive investment in large-scale infrastructure. Pain medicine, by contrast, has no institute of its own—and, with the dismantling of the NIH Office of Pain Policy and Planning this year, it has lost even the limited coordinating presence it once had. This lack of sustained, dedicated funding explains why pain lags far behind oncology in data infrastructure, despite the scope of its burden.

    Cardiology offers another instructive contrast. The American College of Cardiology’s National Cardiovascular Data Registry (ACC-NCDR),9 launched in 1997, has impressively grown into a global standard for cardiovascular outcomes. While initially supported by professional societies and industry, government involvement solidified its longevity and tenure. Centers for Medicare & Medicaid Services (CMS) mandated standardized reporting and quality improvement across several domains – requiring reporting for Medicare coverage. The NCDR now includes at least ten registries that cover a broad range of areas: percutaneous coronary interventions, myocardial infarction, atrial fibrillation, valve therapies, and more. Its standardized data dictionaries, risk-adjustment tools, and integration with electronic medical record (EMR) systems have enabled benchmarking across thousands of institutions, informed ACC and American Heart Association guidelines, shaped payer policy, and guided legislation. Ultimately, cardiology leveraged professional leadership, payer incentives, and government requirements to build a sustained infrastructure that continuously and transparently drives quality and innovation. Pain medicine has had neither oncology’s federal investment nor cardiology’s profession-led registry model. Thus, the field remains fragmented and underpowered to deliver the data revolution patients need.

    Responsibility for building a comprehensive, open-access repository cannot fall on NIH alone. Industry, health systems, and insurers hold enormous amounts of valuable data: clinical trial outcomes, electronic health records, claims, and treatment utilization. Much of this—particularly non-proprietary elements—could be shared without threatening competitive advantage or shareholder responsibilities. Additionally, CMS possesses institutional experience creating and maintaining high-quality, accessible data that assist researchers across many different types of organizations, and they may be able to help integrate patient-level pain management data into the larger data ecosystem. By contributing to a centralized resource, these stakeholders could accelerate discovery, improve understanding of treatment outcomes, and support evidence-based policy and clinical decision-making.

    The need for collaboration is urgent. Chronic pain patients face long waits, geographic disparities, and insurance hurdles, worsened by a shrinking workforce—15.5% of fellowship positions went unfilled in 2023–2024.10 Open-access data can extend the reach of specialists, helping health systems target effective treatments and allocate resources efficiently. Combined with AI, harmonized datasets can reveal treatment-response patterns, predict who will benefit from specific therapies, guide precision care pathways, and support Advanced Practice Providers with decision tools—allowing more patients to receive timely, personalized care.11

    Pain medicine stands at a critical juncture. What it lacks is not just standardized measures, but a centralized, NIH-led repository to bring those measures together at scale. To achieve this, NIH should convene a working group of data managers and curators from academia, industry, health systems, insurers, and patient groups to design and launch such a repository. This group would define the technical and governance details—metadata standards, documentation practices, privacy and consent frameworks, and mechanisms for continuous updating. Drawing on best practices for responsible dataset creation,12 it would ensure that the repository is high-quality, transparent about limitations, and sustainable over time.

    By pairing the standards already in place (CDEs, Toolbox, DCC) with a federated, open-access repository built under NIH leadership, pain medicine can finally realize the same acceleration that oncology and cardiology have achieved. The field does not need more isolated datasets; it needs a coordinated home. NIH is uniquely positioned to build it—and the time to act is now.

    Disclosure

    Dr Shravani Durbhakula reports personal fees from Averitas Pharma, outside the submitted work. Dr Michael Schatman is a senior medical advisor for Apurano Pharma, outside the submitted work. Dr Stephen Bruehl reports personal fees from Akigai and Ambros, during the conduct of the study. The authors report no other conflicts of interest in this work.

    References

    1. Hulsen T. Sharing is caring-data sharing initiatives in healthcare. Int J Environ Res Public Health. 2020;17(9):3046. doi:10.3390/ijerph17093046

    2. Bhattacharya S, Saleem SM, Singh A, Singh S, Tripathi S. Empowering precision medicine: regenerative AI in breast cancer. Front Oncol. 2024;14:1465720. doi:10.3389/fonc.2024.1465720

    3. Chiu YC, Chen HH, Zhang T, et al. Predicting drug response of tumors from integrated genomic profiles by deep neural networks. BMC Med Genomics. 2019;12(Suppl 1):18. doi:10.1186/s12920-018-0460-9

    4. Rikard SM, Strahan AE, Schmit KM, Guy Jr GP. Chronic pain among adults – United States, 2019–2021. Morb Mortal Wkly Rep. 2023;72(15):379–385. doi:10.15585/mmwr.mm7215a1

    5. Guy Jr GP, Miller GF, Legha JK, et al. Economic costs of chronic pain-United States, 2021. Med Care. 2025;63(9):679–685. doi:10.1097/MLR.0000000000002181

    6. United States Department of Health and Human Services. NIH Toolbox. Available from: https://nihtoolbox.org/. Accessed August 20, 2025.

    7. United States Department of Health and Human Services. Common Data Elements (CDEs) Repository. Available from: https://heal.nih.gov/data/common-data-elements-repository. Accessed August 20, 2025.

    8. USNIoNDaSEPPICNE-NAa. Available from: https://www.ninds.nih.gov/current-research/trans-agency-activities/ninds-role-heal-initiative/early-phase-pain-investigation-clinical-network-eppic-net. Accessed August 20, 2025.

    9. American College of Cardiology. National Cardiovascular Data Registry. Available from: https://cvquality.acc.org/NCDR-Home. Accessed August 22, 2025.

    10. Jueng J, Pritzlaff SG, Mehta N, et al. Analyzing trends in the pain fellowship match – A survey of program directors. J Pain Res. 2025;18:2335–2341. doi:10.2147/JPR.S496104

    11. Malaguti MC, Gios L, Giometto B, et al. Artificial intelligence of imaging and clinical neurological data for predictive, preventive and personalized (P3) medicine for Parkinson Disease: the NeuroArtP3 protocol for a multi-center research study. PLoS One. 2024;19(3):e0300127. doi:10.1371/journal.pone.0300127

    12. Orr W, Crawford K. Building better datasets: seven recommendations for responsible design from dataset creators. arXiv:2409.00252. 2024. doi:10.48550/arXiv.2409.00252

    Continue Reading

  • TJ Maxx is a winner as higher prices drive consumers to hunt for value

    TJ Maxx is a winner as higher prices drive consumers to hunt for value

    Continue Reading

  • Royal rift under spotlight: Prince Harry back in UK; will he meet his father King Charles?

    Royal rift under spotlight: Prince Harry back in UK; will he meet his father King Charles?

    File photo of Prince Harry (Pic credit: AP)

    Prince Harry will return to Britain this week, raising fresh speculation that he could reunite with his father, King Charles III, for the first time in nearly 20 months, a move that could mark tentative steps toward mending one of the royal family’s most public rifts.Harry, 40, is scheduled to attend the WellChild Awards on Monday, an annual charity event for seriously ill children that he has long supported. The date coincides with the third anniversary of Queen Elizabeth II’s death, adding poignancy to his visit.While no meeting between father and son has been confirmed, royal commentators believe the timing could provide an opportunity for reconciliation.“There is talk, growing talk, that he might well meet up with his father,” Reuters quoted Simon Perry, People magazine’s royal correspondent in London. “Any time Prince Harry is relatively close to his father and they’re in the same country, there’s going to be speculation.”Buckingham Palace declined to comment, citing its policy of not discussing private family matters. A spokesperson for the Duke of Sussex also refused to confirm or deny whether a meeting was planned.

    Family rift stretches back years

    Harry has been estranged from not only King Charles but also much of the royal family since he and his wife Meghan Markle stepped down as senior royals in 2020 and moved to California.In the years since, Harry has been outspoken in his criticism of the monarchy. Through interviews, the couple’s Netflix series, and his explosive memoir Spare, he delivered particularly sharp rebukes of both his father and elder brother, Prince William.The Duke last saw his father in February 2024, when Buckingham Palace announced that Charles was undergoing cancer treatment. Their meeting was brief, and relations have remained frosty.

    A call for reconciliation

    In May, following a failed legal challenge against the British government over his security arrangements, Harry gave an emotional interview to the BBC in which he spoke candidly about the fractured ties.“Of course some members of my family will never forgive me for writing a book. Of course they will never forgive me for lots of things,” he said. “But I would love reconciliation with my family … there’s no point in continuing to fight anymore. And life is precious.”He added: “I don’t know how much longer my father has. He won’t speak to me because of this security stuff, but it would be nice to reconcile.”


    Continue Reading

  • Buffett’s likely exit from Kraft Heinz is a problem for the mac-and-cheese stock

    Buffett’s likely exit from Kraft Heinz is a problem for the mac-and-cheese stock

    Continue Reading

  • Capstone Copper (TSX:CS) Valuation in Focus After Mantoverde Production Slowdown and Operational Setback

    Capstone Copper (TSX:CS) Valuation in Focus After Mantoverde Production Slowdown and Operational Setback

    Capstone Copper (TSX:CS) is catching the attention of investors after an unexpected setback at its Chilean Mantoverde mine. The company reported sequential failures of both ball mill drive motors during the last week of August, leading to a temporary dip in copper production capacity. With repairs estimated to take about four weeks, Capstone is now operating at roughly half capacity at Mantoverde. The company is aiming to soften the impact by aligning scheduled maintenance with the downtime and maintaining copper output through alternative methods.

    This operational hiccup comes at a time when Capstone Copper has seen notable momentum over the past year. The stock has climbed 23% and experienced a strong surge of 14% in the past month. While this recent event may introduce some near-term uncertainty, it follows a period of significant long-term growth for Capstone, with a sixfold total return over five years and sizable three-year performance. The market’s reaction may reflect shifting views on both the risks and potential upside in the copper sector, especially given Capstone’s history of managing challenges at its operations.

    As the shares adjust to the latest production update, investors may be considering whether this presents an entry point for a company with a record of growth or if the market has already accounted for uncertainties ahead.

    According to the most widely followed narrative, Capstone Copper shares are seen as trading at a notable discount to their estimated fair value. Analyst consensus reflects optimism about the company’s outlook, supported by expectations of robust future growth in both production and profits.

    “The imminent execution of the Mantoverde Optimized project, following recent permit approval, will materially increase throughput and sustain higher copper production at lower incremental cost. This is expected to positively impact both revenue and net margins as expanded volumes are realized.”

    Curious what could justify a fair value higher than today’s stock price? Analysts are banking on transformative operating milestones and the earnings increase they expect from upcoming project completions. The forward-looking math behind the target price is bold and reveals key financial optimism. Want the full breakdown and actual numbers driving this bullish view? Find the details in the narrative’s complete forecast.

    Result: Fair Value of $11.10 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, persistent drought in Arizona or setbacks at key mines could undermine the bullish outlook and challenge analysts’ expectations for Capstone’s growth trajectory.

    Continue Reading

  • Apple AI Lawsuit Alleges Use of Copyrighted Books for Training

    Apple AI Lawsuit Alleges Use of Copyrighted Books for Training

    Apple has been hit with an AI lawsuit in a U.S. federal court, where authors allege the company used copyrighted books without consent or compensation to train its artificial intelligence systems.

    The proposed class action was filed on Friday in the federal court for Northern California by authors Grady Hendrix and Jennifer Roberson. The lawsuit claims that Apple copied protected works without seeking permission, credit or compensation from the writers.

    “Apple has not attempted to pay these authors for their contributions to this potentially lucrative venture,” the filing stated. The lawsuit further alleges that Apple relied on a known body of pirated books to train its large language models under the “OpenELM” project.

    Hendrix, who resides in New York, and Roberson, based in Arizona, said their works were included in the pirated dataset. Apple and legal representatives for the plaintiffs did not immediately respond to media requests for comment.

    The Apple AI lawsuit is the latest in a series of legal challenges targeting major technology firms accused of using copyrighted material to train artificial intelligence systems. Earlier on Friday, AI startup Anthropic disclosed in a California court filing that it had agreed to pay $1.5 billion to settle a class action brought by authors who accused the company of using their works without approval to train its chatbot Claude. Lawyers for the plaintiffs described it as the largest publicly reported copyright recovery in history, though Anthropic did not admit liability.

    In June, Microsoft was also sued by a group of authors alleging their books were used without consent to train its Megatron AI model. Meta Platforms and OpenAI, backed by Microsoft, have faced similar claims over the alleged misuse of copyrighted content.

    The lawsuit against Apple adds to the growing wave of intellectual property disputes surrounding artificial intelligence, as authors, publishers and content creators seek stronger protections in the rapidly evolving AI landscape.

    Continue Reading

  • WCH Tokyo 25 preview: men's 5000m – worldathletics.org

    1. WCH Tokyo 25 preview: men’s 5000m  worldathletics.org
    2. Ingebrigtsen confirms return to track at Tokyo World Athletics Championships  European Athletics
    3. Jakob Ingebrigtsen keeping the faith in race against time  Athletics Weekly
    4. Ingebrigtsen battles injury to compete at Tokyo World Championships  Sportstar
    5. Athletics-Ingebrigtsen battles injury to compete at Tokyo world championships  Devdiscourse

    Continue Reading

  • A Look at Equinix (EQIX) Valuation Following Settlement Progress on Hindenburg-Linked Lawsuit

    A Look at Equinix (EQIX) Valuation Following Settlement Progress on Hindenburg-Linked Lawsuit

    If you have been watching Equinix (EQIX) lately, the finalisation of its settlement agreement with investors is hard to miss. The agreement, which still awaits court approval, wraps up a turbulent chapter that began with a Hindenburg Research report earlier this year. That report accused the company of overstating its Adjusted Funds From Operations by more than 20% in 2023. This disclosure quickly led to a class action lawsuit and introduced uncertainty into the outlook for the world’s largest data center REIT. With the legal overhang now moving toward resolution, investors are recalibrating their expectations for the company’s next phase.

    This development comes at a time of conflicting momentum for Equinix shares. After a challenging period, including a nearly 18% slide year to date and a 3% drop over the past twelve months, the stock’s multi-year performance remains in positive territory with a 25% gain over three years and 13% over five. Despite recent volatility and scrutiny, the company’s latest annual results show revenue up 8% and net income rising 13%. This reflects steady operational progress even as litigation risk has concerned some investors. At yesterday’s close, shares remained well below their earlier peaks, suggesting that market sentiment may still be pricing in reputational and regulatory risks resulting from the Hindenburg report.

    After months of turbulence and renewed focus on valuation, investors are considering whether this is the moment to pick up Equinix at a discount or if the market has already factored in a full recovery.

    The most widely followed narrative sees Equinix as undervalued by nearly 20%, reflecting high expectations for future growth and profitability driven by global digital infrastructure trends.

    Strategic data center expansion and strong customer demand in AI and cloud drive long-term growth and recurring revenue streams. High-margin interconnection services and disciplined capital management support margin expansion and improved earnings per share.

    Curious why Equinix’s growth story is making waves among analysts? There is one detail about future revenue, profit margins, and a bold earnings forecast that is driving their valuation, and it is not what you would expect from most data center REITs. Want to uncover which aggressive assumptions are fueling that surprising price target? Read on to find out how this narrative is re-shaping investor expectations.

    Result: Fair Value of $957 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    Continue Reading

  • Black Coffee to debut at [UNVRS] during Closing Party

    Black Coffee to debut at [UNVRS] during Closing Party

    During the course of the 2025 season, most of The Night League‘s (TNL) talent has passed through to play at the operator’s brand-new [UNVRS] nightclub.

    Everyone from The Martinez Brothers and Joseph Capriati, to HUGEL and Miss Monique have temporarily swapped Hï Ibiza for [UNVRS]. However, one man has remained conspicuous by his absence. That all changes at the Closing Party, when Black Coffee finally debuts.

    On Sunday 12 October, the third and final part of TNL’s Trilogy is capped with the presence of South Africa’s foremost music ambassador – and it’s no less than he’s earned.

    This summer, the arrival of [UNVRS] has shaken up the landscape, but one night which seemed immune to the increased competition was Saturday nights at Hï Ibiza, where Black Coffee continued to reign. Quite the opposite, it has experienced its most successful summer ever.

    Now, after he stood out as the glaring admission from the group making a cross-island excursion, it all becomes clear why. They were saving him for last. Black Coffee is the prize name at the closing. He’ll be in good company.

    [UNVRS]’s peak-season Tuesday night resident Anyma (pictured above) is set to return for the farewell bash, while Salomé Le Chat is another return visitor. She was part of the line-up at the club’s Opening Party at the end of May.

    Adding some catwalk glam, appearances from KEINEMUSIK’s Rampa, Brazilian sensation Vintage Culture and designer/DJ Peggy Gou make this a red carpet affair. Rounding things off, ANOTR complete a hat-trick of [UNVRS] dates and complete the giant line-up.

    [UNVRS]’s Closing Party follows the day after those from TNL’s other two clubs, Ushuaïa & Hï Ibiza.

    Tickets for The Trilogy: Part Three are on sale now and available to buy below.

    Continue Reading